Fitness News
 > Asthma Allergy News
Diabetes News
Women's Health News
Men's Health News

Personal Archive
My Account

About Us
Advertise With Us
Feed Your Site
Contact Us

Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

Macrolide Antibiotics Are Effective for Bronchiectasis
Even though resistance increases, these drugs may help reduce care costs for patients

TUESDAY, March 26 (HealthDay News) -- Macrolide antibiotics are effective in reducing exacerbations in patients with non-cystic fibrosis bronchiectasis, although the resistance rate increases, according to two studies published in the March 27 issue of the Journal of the American Medical Association.

In the first study, Josje Altenburg, M.D., from Medical Centre Alkmaar in the Netherlands, and colleagues randomly assigned 83 patients with non-cystic fibrosis bronchiectasis to placebo or 250 mg daily azithromycin. After 12 months, the researchers found that the median number of exacerbations was significantly lower after azithromycin treatment (zero versus two). Azithromycin treatment also lowered the risk of having at least one exacerbation (46 versus 80 percent of patients; hazard ratio, 0.29) but increased the macrolide resistance rate.

In the second study, David J. Serisier, M.B.B.S., D.M., from Mater Adult Hospital in South Brisbane, Australia, and colleagues randomly assigned 117 patients with non-cystic fibrosis bronchiectasis to placebo or 400 mg erythromycin ethylsuccinate twice daily. After 12 months, the researchers found that erythromycin treatment significantly reduced the mean number of pulmonary exacerbations per patient per year (1.29 versus 1.97). Erythromycin treatment also reduced 24-hour sputum production and attenuated lung function decline but increased the proportion of macrolide-resistant oropharyngeal streptococci.

"Macrolides offer an important and now evidence-based treatment for bronchiectasis and, if used carefully, may help to improve quality of life and reduce health care costs for patients with bronchiectasis," write the authors of an accompanying editorial.

Teva supplied the azithromycin for the first study. The second study was funded by GlaxoSmithKline. Authors from both studies disclosed financial ties to the pharmaceutical industry.

Abstract - Altenburg
Full Text (subscription or payment may be required)
Abstract - Serisier
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Health News Copyright © 2013 HealthDay. All rights reserved.

Back to Top Stories